Literature DB >> 23139292

Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease.

Lisanne C de Vos1, Marjon J Noordzij, Douwe J Mulder, Andries J Smit, Helen L Lutgers, Robin P F Dullaart, Pieter W Kamphuisen, Clark J Zeebregts, Joop D Lefrandt.   

Abstract

OBJECTIVE: Evidence for an important role of advanced glycation end products (AGEs) in the development of atherosclerosis and cardiovascular disease beyond diabetes mellitus and renal disease is growing. Skin autofluorescence (SAF) is a validated noninvasive measure of tissue AGEs. We hypothesized that SAF is elevated in peripheral artery disease (PAD). METHODS AND
RESULTS: A case-control study was performed in 492 patients with PAD and 164 controls, matched for age (mean 66 ± 10 years) and presence of diabetes mellitus. Cardiovascular risk factors and comorbidity (coronary artery disease, cerebrovascular disease, abdominal aortic aneurysm) were assessed. SAF was measured with the AGE Reader. SAF was higher in patients compared with controls: geometric mean 2.77 (95% confidence interval [CI], 2.71-2.83) versus 2.44 (95% CI, 2.35-2.53) arbitrary units, P=0.4×10(-8). In logistic regression, the adjusted odds ratio for the presence of PAD was 2.47 (95% CI, 1.66-3.69) per 1 unit increase of SAF. PAD patients with cardiovascular comorbidity had a higher SAF compared with those without: geometric mean 2.93 (95% CI, 2.85-3.02) versus 2.63 (95% CI, 2.55-2.71) arbitrary units, P=0.4×10(-6), also after correction for confounders. Regression analysis showed that age, smoking, diabetes mellitus, chronic kidney disease, and a history of cerebrovascular disease or abdominal aortic aneurysm were independently associated with SAF in the patients with PAD.
CONCLUSIONS: Accumulation of tissue AGEs is increased in patients with PAD, independent of cardiovascular risk factors and comorbidity, although these conditions are associated with a further increase. These findings underscore the importance of AGEs in PAD, irrespective of the presence of diabetes mellitus and renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23139292     DOI: 10.1161/ATVBAHA.112.300016

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  28 in total

Review 1.  Translational physiology: from molecules to public health.

Authors:  Douglas R Seals
Journal:  J Physiol       Date:  2013-06-03       Impact factor: 5.182

2.  Advanced glycation end products, aortic stiffness, and wave reflection in peritoneal dialysis as compared to hemodialysis.

Authors:  Fabrice Mac-Way; Véronique Couture; Mihai S Utescu; Sophie Ignace; Sacha A De Serres; Renée-Claude Loignon; Karine Marquis; Richard Larivière; Mohsen Agharazii
Journal:  Int Urol Nephrol       Date:  2013-11-17       Impact factor: 2.370

3.  Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.

Authors:  James P Corsetti; Ron T Gansevoort; Stephan J L Bakker; Charles E Sparks; Priya Vart; Robin P F Dullaart
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

4.  Skin autofluorescence, 5-year mortality, and cardiovascular events in peripheral arterial disease: all that glitters is surely not gold.

Authors:  Ann Marie Schmidt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-04       Impact factor: 8.311

Review 5.  Cellular mechanisms and consequences of glycation in atherosclerosis and obesity.

Authors:  Raquel López-Díez; Alexander Shekhtman; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Biochim Biophys Acta       Date:  2016-05-08

6.  Plasma Levels of Advanced Glycation End Products Are Related to the Clinical Presentation and Angiographic Severity of Symptomatic Lower Extremity Peripheral Arterial Disease.

Authors:  Anand Prasad; James R Lane; Sotirios Tsimikas; Ehtisham Mahmud; Srikrishna Khandrika; Peter Bekker; Manjusha Ilapakurti; Dan Nguyen; Amir Ravandi; Travis Israel
Journal:  Int J Angiol       Date:  2015-03-23

7.  Within- and Between-Body-Site Agreement of Skin Autofluorescence Measurements in People With and Without Diabetes-Related Foot Disease.

Authors:  Malindu E Fernando; Robert G Crowther; Peter A Lazzarini; Kunwarjit S Sangla; Scott Wearing; Petra Buttner; Jonathan Golledge
Journal:  J Diabetes Sci Technol       Date:  2019-06-16

8.  Skin Intrinsic Fluorescence and Selected Measures of Visual Function and aging in Older Adults.

Authors:  Barbara E K Klein; Kristine E Lee; John D Maynard; Chris A Johnson; Lorraine Danforth; Ronald Klein
Journal:  Ophthalmic Epidemiol       Date:  2019-04-27       Impact factor: 1.648

Review 9.  Skin Autofluorescence - A Non-invasive Measurement for Assessing Cardiovascular Risk and Risk of Diabetes.

Authors:  Alin Stirban; Lutz Heinemann
Journal:  Eur Endocrinol       Date:  2014-08-28

Review 10.  Recent highlights of ATVB: diabetes mellitus.

Authors:  Ann Marie Schmidt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.